[Androgen receptor variants in prostate cancer].

about

[Androgen receptor variants in prostate cancer].

Item

http://www.wikidata.org/entity/Q49845725

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

[Androgen receptor variants in prostate cancer].

@en

[Androgen receptor variants in prostate cancer].

@nl

type

Item

label

[Androgen receptor variants in prostate cancer].

@en

[Androgen receptor variants in prostate cancer].

@nl

prefLabel

[Androgen receptor variants in prostate cancer].

@en

[Androgen receptor variants in prostate cancer].

@nl

P1476

[Androgen receptor variants in prostate cancer].

@en

P2093

Edwige Schreyer

http://www.w3.org/2001/XMLSchema#string

Frédérique Schaff-Wendling

http://www.w3.org/2001/XMLSchema#string

Félicie Cottard

http://www.w3.org/2001/XMLSchema#string

Jean-Emmanuel Kurtz

http://www.w3.org/2001/XMLSchema#string

Jocelyn Céraline

http://www.w3.org/2001/XMLSchema#string

Pauline Ould Madi-Berthélémy

http://www.w3.org/2001/XMLSchema#string

Philippe Barthélémy

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Prostate cancer stem cells: the role of androgen and estrogen receptors

Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications

A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation.

P304

758-764

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1051/MEDSCI/20173308021

http://www.w3.org/2001/XMLSchema#string

P407

Af-Faransiis

P433

8-9

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28945566

http://www.w3.org/2001/XMLSchema#string